Third Rock Ventures names entrepreneur-in-residence

Tuesday, October 2, 2012 01:57 PM

Boston-based Third Rock Ventures, a venture capital firm focused on building life sciences companies, has named Felix W. Frueh, Ph.D., an entrepreneur-in-residence (EIR). As an EIR, Dr. Frueh will provide strategic input on new and existing portfolio companies with a particular focus on personalized medicine.

Dr. Frueh is a thought leader in personalized medicine, with 15 years of R&D, management and policy experience. Most recently, he was president of the Medco Research Institute, leading Medco's real-world, outcomes-oriented research initiatives and collaborations after having formed Medco's personalized medicine R&D organization.

Previously, Dr. Frueh was associate director for genomics at the FDA, where he built and led the core genomics review team in the Center for Drug Evaluation and Research (CDER) and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group. He has been a member of various working groups on genetics and genomics at the FDA and the Department of Health and Human Services (DHHS). He serves on the board of the Personalized Medicine Coalition and is also a board member at Enterome Biosciences. He is an adjunct faculty member at the Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina and held faculty appointments in the Departments of Pharmacology and Medicine at Georgetown University in Washington, D.C. He was a postdoctoral fellow at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry.

"Throughout my career, I have had the opportunity to see new technologies and innovative approaches in personalized medicine make an impact on the lives of patients," said Dr. Frueh. "I believe that Third Rock's approach to investing in cutting-edge science has the potential to make a tremendous difference, and I look forward to being a part of that effort."

Third Rock Ventures, founded in 2007, has more than $800 million and two funds under management. With offices in Boston and San Francisco, it is focused on working with passionate entrepreneurs in the areas of disruptive science that will make a difference in the lives of patients.




Browse by:


December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs